- In late May 2026, Privia Health Group, Inc. signed a definitive agreement to enter the New Jersey market by partnering with the Neurology Group of Bergen County, a 25-clinician adult and pediatric neurology practice that will anchor Privia Medical Group, New Jersey and is expected to be on the Privia platform by year-end 2026.
- This partnership gives Privia a foothold in a new state while extending its interoperable technology and population health capabilities to community neurologists and their patients across multiple reimbursement models.
- We’ll now examine how using Neurology Group of Bergen County as an anchor practice in New Jersey could influence Privia’s investment narrative.
Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
Privia Health Group Investment Narrative Recap
To own Privia Health, you need to believe its physician enablement model can scale profitably across new states while managing thin margins and evolving payment rules. The New Jersey neurology partnership fits the existing state expansion playbook but does not materially change the near term focus on improving earnings leverage or the key risk around higher labor and technology costs pressuring already low net margins.
The recent Q1 2026 results, with revenue of US$603.85 million and net income of US$3.06 million, are particularly relevant here because they highlight how Privia’s expansion efforts, including Arizona and now New Jersey, must eventually translate into better profitability to support the current valuation and analysts’ expectations for faster earnings growth than the broader US market.
Yet investors should also weigh how growing dependence on new market entries could expose them to...
Read the full narrative on Privia Health Group (it's free!)
Privia Health Group's narrative projects $3.0 billion revenue and $92.7 million earnings by 2029. This requires 10.6% yearly revenue growth and about a $70.9 million earnings increase from $21.8 million today.
Uncover how Privia Health Group's forecasts yield a $31.60 fair value, a 46% upside to its current price.
Exploring Other Perspectives
Three fair value estimates from the Simply Wall St Community cluster between US$30.10 and US$39.60 per share, underscoring how differently individual investors can view Privia’s potential. You should set those views against the company’s reliance on successful state expansion as a key driver of future performance and consider several contrasting opinions before deciding what this could mean for you.
Explore 3 other fair value estimates on Privia Health Group - why the stock might be worth just $30.10!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Privia Health Group research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Privia Health Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Privia Health Group's overall financial health at a glance.
Interested In Other Possibilities?
Our top stock finds are flying under the radar-for now. Get in early:
- Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com